FindTrial
Sign In

To identify the NIFTP(Non invasive follicular thyroid neoplasm with papillary like nuclear features) by using certain IHC markers on follicular adenomas. Both are encapsulated lesions.

EXPRESSION OF CK19, CD56,CD57 IN FOLLICULAR ADENOMAS.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/12/038833
Enrollment
20
Registered
2021-12-22
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C73- Malignant neoplasm of thyroid gland

Interventions

Control Intervention1: NIL: NIL

Sponsors

Maulana Azad Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.All cases of follicular adenomas. 2.Capsule completely processed.

Exclusion criteria

Exclusion criteria: 1.Other histology, diffuse infiltrative lesions. 2.Multiple foci of tumor and ruptured capsule.

Design outcomes

Primary

MeasureTime frame
Expression of CK19,CD 56, CD 57 in follicular adenomas.Timepoint: 4-8 weeks.—

Secondary

MeasureTime frame
Based on the expression of these markers differentiating follicular adenomas from NIFTP.Timepoint: one year—

Countries

India

Contacts

Public ContactDr M Bharanidharan

Maulana Azad Medical College,

meetamamc@gmail.com9968604327

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026